Letter to the EditorIn reply to “Small, however significant differences in the definition of physical frailty and sarcopenia”
Section snippets
Competing interests statement
M.C., R.C., F.L., and E.M. are partners of the SPRINTT Consortium, which is partly funded by the European Federation of Pharmaceutical Industries and Associations (EFPIA). M.C. served as a consultant for and/or received honoraria for scientific presentations from Nestlé and 4D Pharma PLC. R.C. served as a consultant for Novartis. E.M. served as a consultant for Huron Consulting Group, Genactis, and Novartis.
References (10)
- et al.
The "BIOmarkers associated with Sarcopenia and PHysical frailty in EldeRly pErsons" (BIOSPHERE) study: Rationale, design and methods
Eur J Intern Med
(2018) Sarcopenia: diagnosis and treatment
J Nutr Health Aging
(2008)- et al.
The essence of frailty: a systematic review and qualitative synthesis on frailty concepts and definitions
Eur J Intern Med
(2018) - et al.
Small, however significant differences in the definition of physical frailty, and sarcopenia
Eur J Intern Med
(2018) - et al.
Frailty in older adults: evidence for a phenotype
J Gerontol A Biol Sci Med Sci
(2001)
There are more references available in the full text version of this article.
Cited by (0)
© 2019 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.